Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Jiangsu Hengrui Pharmaceuticals Co (HK:1276) made a powerful entrance on the Hong Kong Stock Exchange on Friday, with shares soaring over 37% in early trading after a $1.27 billion IPO. The offering was priced at HK$44.05—at the top of its range—reflecting strong investor appetite for the Chinese biopharmaceutical giant.
Shares opened at HK$57.10, marking a 29.6% jump from the offer price, and peaked at HK$60.20 shortly after the market opened. The robust debut highlights renewed investor confidence in Hong Kong’s IPO market, which has seen a notable resurgence, particularly from mainland Chinese companies pursuing dual listings.
Hengrui, already publicly traded in Shanghai, is one of China’s top drugmakers, specializing in oncology, innovative therapies, and biosimilars. The company plans to allocate IPO proceeds to accelerate clinical trials, scale production capabilities, and support global expansion. The strategic move is aimed at strengthening its international footprint and enhancing its competitiveness in the global pharmaceutical industry.
The timing of Hengrui’s successful listing coincides with the broader uptick in Hong Kong’s capital markets. Earlier this week, Contemporary Amperex Technology Co Ltd (CATL) (HK:3750) also debuted strongly, underscoring heightened interest in high-growth Chinese firms across sectors.
Jiangsu Hengrui’s performance signals positive momentum for biotech and pharmaceutical IPOs in Asia, particularly as global investors look toward companies with robust pipelines and innovation-driven strategies. With a clear focus on global growth and R&D, Hengrui's dual listing positions it to attract more institutional interest while reinforcing Hong Kong’s status as a hub for health tech and biotech capital.
